{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T03:28:24Z","timestamp":1793330904461,"version":"4.5.0"},"reference-count":42,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2019,10,16]],"date-time":"2019-10-16T00:00:00Z","timestamp":1571184000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2019,10,16]],"date-time":"2019-10-16T00:00:00Z","timestamp":1571184000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/501100004320","name":"Shiraz University of Medical Sciences","doi-asserted-by":"crossref","award":["17-16022 and 17-16041"],"award-info":[{"award-number":["17-16022 and 17-16041"]}],"id":[{"id":"10.13039\/501100004320","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Arch Dermatol Res"],"published-print":{"date-parts":[[2020,3]]},"DOI":"10.1007\/s00403-019-01996-9","type":"journal-article","created":{"date-parts":[[2019,10,16]],"date-time":"2019-10-16T07:03:03Z","timestamp":1571209383000},"page":"123-131","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":68,"title":["Predominant role of innate pro-inflammatory cytokines in vitiligo disease"],"prefix":"10.1007","volume":"312","author":[{"given":"Nasser","family":"Gholijani","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammad-Reza","family":"Yazdani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ladan","family":"Dastgheib","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,10,16]]},"reference":[{"key":"1996_CR1","doi-asserted-by":"publisher","DOI":"10.1155\/2015\/196537","author":"ACG Abreu","year":"2015","unstructured":"Abreu ACG, Duarte GG, Miranda JYP, Ramos DG, Ramos CG, Ramos MG (2015) Immunological parameters associated with vitiligo treatments: a literature review based on clinical studies. Autoimmune Dis. \nhttps:\/\/doi.org\/10.1155\/2015\/196537","journal-title":"Autoimmune Dis"},{"key":"1996_CR2","doi-asserted-by":"publisher","DOI":"10.1155\/2015\/423490","author":"Y Ala","year":"2015","unstructured":"Ala Y, Pasha MK, Rao RN, Komaravalli PL, Jahan P (2015) Association of IFN-\u03b3: IL-10 cytokine ratio with Nonsegmental Vitiligo pathogenesis. Autoimmune Dis. \nhttps:\/\/doi.org\/10.1155\/2015\/423490","journal-title":"Autoimmune Dis"},{"issue":"2","key":"1996_CR3","doi-asserted-by":"publisher","first-page":"65","DOI":"10.4103\/2349-5847.219673","volume":"4","author":"AK Arora","year":"2017","unstructured":"Arora AK, Kumaran MS (2017) Pathogenesis of vitiligo: an update. Pigment Int 4(2):65\u201377. \nhttps:\/\/doi.org\/10.4103\/2349-5847.219673","journal-title":"Pigment Int"},{"issue":"2","key":"1996_CR4","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1016\/j.jaad.2008.09.048","volume":"60","author":"PY Basak","year":"2009","unstructured":"Basak PY, Adiloglu AK, Ceyhan AM, Tas T, Akkaya VB (2009) The role of helper and regulatory T cells in the pathogenesis of vitiligo. J Am Acad Dermatol 60(2):256\u2013260. \nhttps:\/\/doi.org\/10.1016\/j.jaad.2008.09.048","journal-title":"J Am Acad Dermatol"},{"issue":"8","key":"1996_CR5","doi-asserted-by":"publisher","first-page":"992","DOI":"10.1111\/j.1365-4632.2006.02744.x","volume":"45","author":"A Birol","year":"2006","unstructured":"Birol A, Kisa U, Kurtipek GS, Kara F, Kocak M, Erkek E, Caglayan O (2006) Increased tumor necrosis factor alpha (TNF-\u03b1) and interleukin 1 alpha (IL1-\u03b1) levels in the lesional skin of patients with nonsegmental vitiligo. Int J Dermatol 45(8):992\u2013993. \nhttps:\/\/doi.org\/10.1111\/j.1365-4632.2006.02744.x","journal-title":"Int J Dermatol"},{"issue":"4","key":"1996_CR6","doi-asserted-by":"publisher","first-page":"204","DOI":"10.4274\/turkderm.82957","volume":"48","author":"FP Cengiz","year":"2014","unstructured":"Cengiz FP, Emiro\u011flu N, \u00c7evirgen Cemil B, Erdem \u00dcGB, Kemeriz F (2014) Serum IL-23 levels in patients with vitiligo. Turkderm 48(4):204\u2013207. \nhttps:\/\/doi.org\/10.4274\/turkderm.82957","journal-title":"Turkderm"},{"issue":"3","key":"1996_CR7","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1016\/j.jaut.2008.04.017","volume":"31","author":"V Dardalhon","year":"2008","unstructured":"Dardalhon V, Korn T, Kuchroo VK, Anderson AC (2008) Role of Th1 and Th17 cells in organ-specific autoimmunity. J Autoimmun 31(3):252\u2013256. \nhttps:\/\/doi.org\/10.1016\/j.jaut.2008.04.017","journal-title":"J Autoimmun"},{"issue":"4","key":"1996_CR8","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1080\/09674845.2014.11669980","volume":"71","author":"J Farhan","year":"2014","unstructured":"Farhan J, Al-Shobaili H, Zafar U, Al Salloom A, Meki A, Rasheed Z (2014) Interleukin-6: a possible inflammatory link between vitiligo and type 1 diabetes. Br J Biomed Sci 71(4):151\u2013157. \nhttps:\/\/doi.org\/10.1080\/09674845.2014.11669980","journal-title":"Br J Biomed Sci"},{"issue":"1","key":"1996_CR9","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1111\/imr.12369","volume":"269","author":"JE Harris","year":"2016","unstructured":"Harris JE (2016) Cellular stress and innate inflammation in organ-specific autoimmunity: lessons learned from vitiligo. Immunol Rev 269(1):11\u201325. \nhttps:\/\/doi.org\/10.1111\/imr.12369","journal-title":"Immunol Rev"},{"issue":"7","key":"1996_CR10","doi-asserted-by":"publisher","first-page":"1869","DOI":"10.1038\/jid.2011.463","volume":"132","author":"JE Harris","year":"2012","unstructured":"Harris JE, Harris TH, Weninger W, Wherry EJ, Hunter CA, Turka LA (2012) A mouse model of vitiligo with focused epidermal depigmentation requires IFN-\u03b3 for autoreactive CD8+ T-cell accumulation in the skin. J Investig Dermatol 132(7):1869\u20131876. \nhttps:\/\/doi.org\/10.1038\/jid.2011.463","journal-title":"J Investig Dermatol"},{"issue":"4","key":"1996_CR11","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1016\/j.autrev.2015.12.006","volume":"15","author":"G Iannella","year":"2016","unstructured":"Iannella G, Greco A, Didona D, Didona B, Granata G, Manno A, Pasquariello B, Magliulo G (2016) Vitiligo: pathogenesis, clinical variants and treatment approaches. Autoimmun Rev 15(4):335\u2013343. \nhttps:\/\/doi.org\/10.1016\/j.autrev.2015.12.006","journal-title":"Autoimmun Rev"},{"issue":"4","key":"1996_CR12","doi-asserted-by":"publisher","first-page":"e35719","DOI":"10.17795\/jssc35719","volume":"2","author":"Z Jadali","year":"2015","unstructured":"Jadali Z (2015) IFN-\u03b3 Promotes Apoptosis of Melanocytes in Vitiligo. J Skin Stem Cell 2(4):e35719. \nhttps:\/\/doi.org\/10.17795\/jssc35719","journal-title":"J Skin Stem Cell"},{"issue":"4","key":"1996_CR13","doi-asserted-by":"publisher","first-page":"e00010","DOI":"10.1128\/CVI.00010-17","volume":"24","author":"SJ Jordan","year":"2017","unstructured":"Jordan SJ, Gupta K, Ogendi BM, Bakshi RK, Kapil R, Press CG, Sabbaj S, Lee JY, Geisler WM (2017) The predominant CD4+ Th1 cytokine elicited to Chlamydia trachomatis infection in women is tumor necrosis factor alpha and not interferon gamma. Clin Vaccine Immunol 24(4):e00010\u2013e00017. \nhttps:\/\/doi.org\/10.1128\/CVI.00010-17","journal-title":"Clin Vaccine Immunol"},{"issue":"4","key":"1996_CR14","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1139\/bcb-2016-0228","volume":"95","author":"RA Karam","year":"2017","unstructured":"Karam RA, Zidan HE, Khater MH (2017) Genetic variants of interferon-gamma and its mRNA expression and inflammatory parameters in the pathogenesis of vitiligo. Biochem Cell Biol 95(4):474\u2013481. \nhttps:\/\/doi.org\/10.1139\/bcb-2016-0228","journal-title":"Biochem Cell Biol"},{"issue":"10","key":"1996_CR15","doi-asserted-by":"publisher","first-page":"1","DOI":"10.9734\/BJMMR\/2016\/23959","volume":"13","author":"E Kasumagic-Halilovic","year":"2016","unstructured":"Kasumagic-Halilovic E, Ovcina-Kurtovic N, Soskic S, Helppikangas H, Ridic O (2016) Serum levels of interleukin-2 and interleukin-2 soluble receptor in patients with vitiligo. Br J Med Med Res 13(10):1\u20137. \nhttps:\/\/doi.org\/10.9734\/BJMMR\/2016\/23959","journal-title":"Br J Med Med Res"},{"issue":"20","key":"1996_CR16","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1017\/S1462399401003362","volume":"3","author":"EH Kemp","year":"2001","unstructured":"Kemp EH, Waterman EA, Weetman AP (2001) Immunological pathomechanisms in vitiligo. Expert Rev Mol Med 3(20):1\u201322. \nhttps:\/\/doi.org\/10.1017\/S1462399401003362","journal-title":"Expert Rev Mol Med"},{"issue":"3","key":"1996_CR17","doi-asserted-by":"publisher","first-page":"510","DOI":"10.1016\/j.jaad.2011.07.018","volume":"66","author":"R Khan","year":"2012","unstructured":"Khan R, Gupta S, Sharma A (2012) Circulatory levels of T-cell cytokines (interleukin [IL]-2, IL-4, IL-17, and transforming growth factor-\u03b2) in patients with vitiligo. J Am Acad Dermatol 66(3):510\u2013511. \nhttps:\/\/doi.org\/10.1016\/j.jaad.2011.07.018","journal-title":"J Am Acad Dermatol"},{"issue":"4","key":"1996_CR18","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1016\/j.immuni.2004.08.018","volume":"21","author":"JK Kolls","year":"2004","unstructured":"Kolls JK, Lind\u00e9n A (2004) Interleukin-17 family members and inflammation. Immunity 21(4):467\u2013476. \nhttps:\/\/doi.org\/10.1016\/j.immuni.2004.08.018","journal-title":"Immunity"},{"issue":"1","key":"1996_CR19","doi-asserted-by":"publisher","first-page":"19","DOI":"10.4103\/0378-6323.90942","volume":"78","author":"R Kumar","year":"2012","unstructured":"Kumar R, Parsad D (2012) Melanocytorrhagy and apoptosis in vitiligo: connecting jigsaw pieces. Indian J Dermatol Venereol Leprol 78(1):19\u201323. \nhttps:\/\/doi.org\/10.4103\/0378-6323.90942","journal-title":"Indian J Dermatol Venereol Leprol"},{"issue":"2","key":"1996_CR20","doi-asserted-by":"publisher","first-page":"S38","DOI":"10.1016\/j.jisp.2016.10.023","volume":"18","author":"IC Le Poole","year":"2017","unstructured":"Le Poole IC, Replenishing MS (2017) Regulatory T cells to halt depigmentation in vitiligo. J Investig Dermatol Symp Proc 18(2):S38\u2013S45. \nhttps:\/\/doi.org\/10.1016\/j.jisp.2016.10.023","journal-title":"J Investig Dermatol Symp Proc"},{"issue":"5","key":"1996_CR21","doi-asserted-by":"publisher","first-page":"e37513","DOI":"10.1371\/journal.pone.0037513","volume":"7","author":"Y Lili","year":"2012","unstructured":"Lili Y, Yi W, Ji Y, Yue S, Weimin S, Ming L (2012) Global activation of CD8+ cytotoxic T lymphocytes correlates with an impairment in regulatory T cells in patients with generalized vitiligo. PLoS One 7(5):e37513. \nhttps:\/\/doi.org\/10.1371\/journal.pone.0037513","journal-title":"PLoS One"},{"issue":"2","key":"1996_CR22","first-page":"18","volume":"2","author":"T Lotti","year":"2015","unstructured":"Lotti T (2015) New frontiers in vitiligo treatment: the low dose cytokines-based therapy. Med Case Rep 2(2):18","journal-title":"Med Case Rep"},{"issue":"3","key":"1996_CR23","doi-asserted-by":"publisher","first-page":"221","DOI":"10.12998\/wjcc.v3.i3.221","volume":"3","author":"GF Mohammed","year":"2015","unstructured":"Mohammed GF, Gomaa AH, Al-Dhubaibi MS (2015) Highlights in pathogenesis of vitiligo. World J Clin Cases 3(3):221\u2013230. \nhttps:\/\/doi.org\/10.12998\/wjcc.v3.i3.221","journal-title":"World J Clin Cases"},{"issue":"3","key":"1996_CR24","doi-asserted-by":"publisher","first-page":"167","DOI":"10.2165\/00128071-200102030-00006","volume":"2","author":"MD Njoo","year":"2001","unstructured":"Njoo MD, Westerhof W (2001) Vitiligo. Am J Clin Dermato 2(3):167\u2013181. \nhttps:\/\/doi.org\/10.2165\/00128071-200102030-00006","journal-title":"Am J Clin Dermato"},{"issue":"6","key":"1996_CR25","doi-asserted-by":"publisher","first-page":"635","DOI":"10.4103\/0019-5154.169136","volume":"60","author":"AM Osman","year":"2015","unstructured":"Osman AM, Mukhtar MM, Bakheit KH, Hamdan HZ (2015) Plasma levels of interleukin-17, interleukin-23, and transforming growth factor-\u03b2 in Sudanese patients with vitiligo: a case\u2013control study. Indian J Dermatol 60(6):635. \nhttps:\/\/doi.org\/10.4103\/0019-5154.169136","journal-title":"Indian J Dermatol"},{"issue":"6","key":"1996_CR26","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1016\/j.coi.2013.10.010","volume":"25","author":"JM Richmond","year":"2013","unstructured":"Richmond JM, Frisoli ML, Harris JE (2013) Innate immune mechanisms in vitiligo: danger from within. Curr Opin Immunol 25(6):676\u2013682. \nhttps:\/\/doi.org\/10.1016\/j.coi.2013.10.010","journal-title":"Curr Opin Immunol"},{"issue":"2","key":"1996_CR27","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1111\/j.1600-0625.2007.00666_2.x","volume":"17","author":"KU Schallreuter","year":"2008","unstructured":"Schallreuter KU (2008) Viewpoint 1. Exp Dermatol 17(2):141\u2013144. \nhttps:\/\/doi.org\/10.1111\/j.1600-0625.2007.00666_2.x","journal-title":"Exp Dermatol"},{"key":"1996_CR28","doi-asserted-by":"publisher","DOI":"10.4172\/2161-1009.1000273","author":"M Singh","year":"2016","unstructured":"Singh M, Mansuri MS, Parasrampuria M, Begum R (2016) Interleukin 1-\u03b1: a modulator of melanocyte homeostasis in vitiligo. Biochem Anal Biochem. \nhttps:\/\/doi.org\/10.4172\/2161-1009.1000273","journal-title":"Biochem Anal Biochem"},{"issue":"4","key":"1996_CR29","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1016\/j.autrev.2016.01.004","volume":"15","author":"RK Singh","year":"2016","unstructured":"Singh RK, Lee KM, Vujkovic-Cvijin I, Ucmak D, Farahnik B, Abrouk M, Nakamura M, Zhu TH, Bhutani T, Wei M, Liao W (2016) The role of IL-17 in vitiligo: a review. Autoimmun Rev 15(4):397\u2013404. \nhttps:\/\/doi.org\/10.1016\/j.autrev.2016.01.004","journal-title":"Autoimmun Rev"},{"issue":"1","key":"1996_CR30","doi-asserted-by":"publisher","first-page":"12","DOI":"10.4103\/0019-5154.92668","volume":"57","author":"S Singh","year":"2012","unstructured":"Singh S, Singh U, Pandey S (2012) Serum concentration of IL-6, IL-2, TNF-\u03b1, and IFN\u03b3 in vitiligo patients. Indian J Dermatol 57(1):12\u201314. \nhttps:\/\/doi.org\/10.4103\/0019-5154.92668","journal-title":"Indian J Dermatol"},{"issue":"6","key":"1996_CR31","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1007\/s40257-017-0298-5","volume":"18","author":"R Speeckaert","year":"2017","unstructured":"Speeckaert R, van Geel N (2017) Vitiligo: an update on pathophysiology and treatment options. Am J Clin Dermatol 18(6):733\u2013744. \nhttps:\/\/doi.org\/10.1007\/s40257-017-0298-5","journal-title":"Am J Clin Dermatol"},{"issue":"2","key":"1996_CR32","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1038\/jid.2011.321","volume":"132","author":"RA Spritz","year":"2012","unstructured":"Spritz RA (2012) Six decades of vitiligo genetics: genome-wide studies provide insights into autoimmune pathogenesis. J Invest Dermatol 132(2):268\u2013273. \nhttps:\/\/doi.org\/10.1038\/jid.2011.321","journal-title":"J Invest Dermatol"},{"issue":"6","key":"1996_CR33","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1007\/s00005-015-0344-z","volume":"63","author":"J Tabarkiewicz","year":"2015","unstructured":"Tabarkiewicz J, Pogoda K, Karczmarczyk A, Pozarowski P, Giannopoulos K (2015) The role of IL-17 and Th17 lymphocytes in autoimmune diseases. Arch Immunol Ther Exp 63(6):435\u2013449. \nhttps:\/\/doi.org\/10.1007\/s00005-015-0344-z","journal-title":"Arch Immunol Ther Exp"},{"key":"1996_CR34","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.cca.2013.05.005","volume":"424","author":"MK Tembhre","year":"2013","unstructured":"Tembhre MK, Sharma VK, Sharma A, Chattopadhyay P, Gupta S (2013) T helper and regulatory T cell cytokine profile in active, stable and narrow band ultraviolet B treated generalized vitiligo. Clin Chim Acta 424:27\u201332. \nhttps:\/\/doi.org\/10.1016\/j.cca.2013.05.005","journal-title":"Clin Chim Acta"},{"issue":"6","key":"1996_CR35","doi-asserted-by":"publisher","first-page":"672","DOI":"10.1111\/ijd.12392","volume":"54","author":"M Vaccaro","year":"2015","unstructured":"Vaccaro M, Cannav\u00f2 SP, Imbesi S, Cristani M, Barbuzza O, Tigano V, Gangemi S (2015) Increased serum levels of interleukin-23 circulating in patients with non-segmental generalized vitiligo. Int J Dermatol 54(6):672\u2013674. \nhttps:\/\/doi.org\/10.1111\/ijd.12392","journal-title":"Int J Dermatol"},{"issue":"9","key":"1996_CR36","doi-asserted-by":"publisher","first-page":"2220","DOI":"10.1038\/jid.2009.32","volume":"129","author":"JG van den Boorn","year":"2009","unstructured":"van den Boorn JG, Konijnenberg D, Dellemijn TA, van der Veen JP, Bos JD, Melief CJ, Vyth-Dreese FA, Luiten RM (2009) Autoimmune destruction of skin melanocytes by perilesional T cells from vitiligo patients. J Invest Dermatol 129(9):2220\u20132232. \nhttps:\/\/doi.org\/10.1038\/jid.2009.32","journal-title":"J Invest Dermatol"},{"issue":"2","key":"1996_CR37","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1016\/j.immuni.2006.01.001","volume":"24","author":"M Veldhoen","year":"2006","unstructured":"Veldhoen M, Hocking RJ, Atkins CJ, Locksley RM, Stockinger B (2006) TGF\u03b2 in the context of an inflammatory cytokine milieu supports de novo differentiation of IL-17-producing T cells. Immunity 24(2):179\u2013189. \nhttps:\/\/doi.org\/10.1016\/j.immuni.2006.01.001","journal-title":"Immunity"},{"issue":"4","key":"1996_CR38","doi-asserted-by":"publisher","first-page":"e18907","DOI":"10.1371\/journal.pone.0018907","volume":"6","author":"CQ Wang","year":"2011","unstructured":"Wang CQ, Cruz-Inigo AE, Fuentes-Duculan J, Moussai D, Gulati N, Sullivan-Whalen M, Gilleaudeau P, Cohen JA, Krueger JG (2011) Th17 cells and activated dendritic cells are increased in vitiligo lesions. PLoS ONE 6(4):e18907. \nhttps:\/\/doi.org\/10.1371\/journal.pone.0018907","journal-title":"PLoS ONE"},{"issue":"4","key":"1996_CR39","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1016\/j.cell.2008.03.036","volume":"133","author":"L Wang","year":"2008","unstructured":"Wang L, Du F, Wang X (2008) TNF-\u03b1 induces two distinct caspase-8 activation pathways. Cell 133(4):693\u2013703. \nhttps:\/\/doi.org\/10.1016\/j.cell.2008.03.036","journal-title":"Cell"},{"issue":"6","key":"1996_CR40","doi-asserted-by":"publisher","first-page":"664","DOI":"10.2340\/00015555-2080","volume":"95","author":"L Yang","year":"2015","unstructured":"Yang L, Wei Y, Sun Y, Shi W, Yang J, Zhu L, Li M (2015) Interferon-gamma inhibits melanogenesis and induces apoptosis in melanocytes: a pivotal role of CD8+ cytotoxic T lymphocytes in vitiligo. Acta Derm Venereol 95(6):664\u2013670. \nhttps:\/\/doi.org\/10.2340\/00015555-2080","journal-title":"Acta Derm Venereol"},{"issue":"12","key":"1996_CR41","doi-asserted-by":"publisher","first-page":"e51040","DOI":"10.1371\/journal.pone.0051040","volume":"7","author":"R Yu","year":"2013","unstructured":"Yu R, Broady R, Huang Y, Wang Y, Yu J, Gao M, Levings M, Wei S, Zhang S, Xu A, Su M, Dutz J, Zhang X, Zhou Y (2013) Correction: transcriptome analysis reveals markers of aberrantly activated innate immunity in vitiligo lesional and non-lesional skin. PLoS ONE 7(12):e51040. \nhttps:\/\/doi.org\/10.1371\/journal.pone.0051040","journal-title":"PLoS ONE"},{"issue":"1","key":"1996_CR42","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1038\/jid.2008.194","volume":"129","author":"LC Zaba","year":"2009","unstructured":"Zaba LC, Fuentes-Duculan J, Eungdamrong NJ, Abello MV, Novitskaya I, Pierson KC, Gonzalez J, Krueger JG, Lowes MA (2009) Psoriasis is characterized by accumulation of immunostimulatory and Th1\/Th17 cell-polarizing myeloid dendritic cells. J Invest Dermatol 129(1):79\u201388. \nhttps:\/\/doi.org\/10.1038\/jid.2008.194","journal-title":"J Invest Dermatol"}],"container-title":["Archives of Dermatological Research"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00403-019-01996-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00403-019-01996-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00403-019-01996-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,10,14]],"date-time":"2020-10-14T23:40:03Z","timestamp":1602718803000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00403-019-01996-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,10,16]]},"references-count":42,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2020,3]]}},"alternative-id":["1996"],"URL":"https:\/\/doi.org\/10.1007\/s00403-019-01996-9","relation":{},"ISSN":["0340-3696","1432-069X"],"issn-type":[{"value":"0340-3696","type":"print"},{"value":"1432-069X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,10,16]]},"assertion":[{"value":"18 June 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 August 2019","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 October 2019","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 October 2019","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance ethical standards"}},{"value":"The authors declare no conflicts of interest. The authors alone are responsible for the content of this manuscript.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All applicable international, national, and institutional guidelines for including patients and controls were followed.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}]}}